FreeTheAI

DocMorris Hits Q3 EBITDA Breakeven and Raises Full-Year 2026 Outlook

BullishHigh impact
DOCMCHF 14.00 4.55%

DocMorris Ltd (DOCM) reported an operating milestone in the third quarter of 2026, reaching adjusted EBITDA breakeven with CHF 0.6 million. The online pharmacy group saw prescription sales growth accelerate to 78% during the quarter. Following these results, the company raised its full-year 2026 financial guidance for both revenue and adjusted EBITDA.

The earlier-than-expected turn to profitability helps ease concerns regarding near-term cash burn and financial stability. Additionally, the business addressed its debt obligations by exchanging CHF 49.6 million of convertible bonds maturing in 2028 for a new bond issue due in 2031. This refinancing extends debt maturities and lowers financing costs, providing further balance-sheet flexibility.

Looking ahead, investors will be monitoring whether the company can maintain positive EBITDA in upcoming quarters and sustain high prescription growth. Management is aiming to reach free cash flow breakeven by 2027, which would allow the company to self-fund its ongoing operations.

Key points

  • DocMorris reached Q3 2026 adjusted EBITDA breakeven at CHF 0.6 million ahead of schedule.
  • The company increased its full-year 2026 outlook for both revenue and adjusted EBITDA.
  • Prescription sales growth surged to 78% during the third quarter.
  • DocMorris extended its debt profile by swapping CHF 49.6 million in 2028 bonds for new 2031 convertibles.
  • Management set a target to achieve free cash flow breakeven by 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were DocMorris's Q3 2026 financial results?

DocMorris reached adjusted EBITDA breakeven in Q3 2026, delivering CHF 0.6 million. Prescription sales growth accelerated to 78% during the quarter, prompting the company to raise its full-year 2026 guidance for revenue and EBITDA.

How did DocMorris refinance its debt?

DocMorris swapped CHF 49.6 million of convertible bonds due in 2028 for new convertible bonds maturing in 2031, extending its debt maturity profile and lowering financing risk.

When does DocMorris expect to reach free cash flow breakeven?

DocMorris targets reaching free cash flow breakeven by 2027.